Suppr超能文献

[吸入性类固醇撤药对慢性阻塞性肺疾病的影响]

[The effects of inhaled steroids withdrawal in COPD].

作者信息

Jebrak G, Honore I, Serrier P, Dumoulin J, Terrioux P, Soyez F, Maurer C, Mangiapan G, Febvre M, Couderc L-J, Braun J-M, Chinet T

机构信息

Service de pneumologie B et de transplantations pulmonaires, hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.

Service de pneumologie, hôpital Cochin, 75679 Paris cedex 14, France.

出版信息

Rev Mal Respir. 2017 Oct;34(8):820-833. doi: 10.1016/j.rmr.2016.10.880. Epub 2017 May 12.

Abstract

The key pathophysiological feature of chronic obstructive pulmonary disease (COPD) is an abnormal inflammatory bronchial reaction after inhalation of toxic substances. The priority is the avoidance of such toxic inhalations, but the use of anti-inflammatory drugs also seems appropriate, especially corticosteroids that are the sole anti-inflammatory drug available for this purpose in France. The risks associated with the prolonged use of these parenteral drugs are well known. Inhalation is therefore the optimal route, but inhaled drugs may also lead to adverse consequences. In COPD, there is an inhaled corticosteroids overuse, and a non-satisfactory respect of the guidelines. Consequently, their withdrawal should be considered. We reviewed seven clinical studies dealing with inhaled corticosteroids withdrawal in patients with COPD and found that included populations were heterogenous with different concomitant treatments. In non-frequent exacerbators receiving inhaled corticosteroids outside the recommendations, withdrawal appears to be safe under a well-managed bronchodilator treatment. In patients with severe COPD and frequent exacerbations, the risk of acute respiratory event is low when they receive concomitant optimal inhaled bronchodilators. However, other risks may be observed (declining lung function, quality of life) and a discussion of each case should be performed, especially in case of COPD and asthma overlap.

摘要

慢性阻塞性肺疾病(COPD)的关键病理生理特征是吸入有毒物质后出现异常的支气管炎症反应。首要任务是避免此类有毒物质的吸入,但使用抗炎药物似乎也很合适,尤其是皮质类固醇,在法国它是唯一可用于此目的的抗炎药物。长期使用这些肠胃外给药药物的风险是众所周知的。因此,吸入是最佳给药途径,但吸入药物也可能导致不良后果。在COPD中,存在吸入性皮质类固醇使用过度的情况,且对指南的遵循情况不尽人意。因此,应考虑停用它们。我们回顾了七项关于COPD患者停用吸入性皮质类固醇的临床研究,发现纳入的人群具有异质性,且伴随的治疗方法各不相同。在未按推荐使用吸入性皮质类固醇的非频繁急性加重患者中,在管理良好的支气管扩张剂治疗下,停用似乎是安全的。在重度COPD且频繁急性加重的患者中,当他们同时接受最佳吸入性支气管扩张剂治疗时,急性呼吸事件的风险较低。然而,可能会观察到其他风险(肺功能下降、生活质量下降),应针对每个病例进行讨论, 尤其是在COPD和哮喘重叠的情况下。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验